Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Pharma & Biotech
Pharma & Biotech
Merck may have solved the hidden problem behind the oral PCSK9 race
Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.
Pharma & Biotech
Why Oragenics, Inc. is betting on CardioDialysis technology to expand its TBI platform
Why is Oragenics, Inc. expanding into CardioDialysis for TBI treatment? Explore the strategy, risks, and future implications today.
Pharma & Biotech
How AIM ImmunoTech Inc. is positioning Ampligen to overcome checkpoint inhibitor resistance in ovarian cancer
Can AIM ImmunoTech Inc.’s Ampligen improve checkpoint inhibitor responses in ovarian cancer? Explore the Phase 2 findings and implications.
Pharma & Biotech
Viridian Therapeutics financing puts thyroid eye disease expansion strategy in sharper focus
Viridian has TED trial wins, but market entry needs capital. See why its $350m raise matters before commercialization.
Pharma & Biotech
Why Cartography Biosciences’ Phase 1 colorectal cancer trial matters after Samsung Ventures backing
Samsung wants oncology optionality beyond manufacturing. Cartography’s Phase 1 T-cell engager puts platform biology under pressure.
Pharma & Biotech
Why Knox Lane is taking Cross Country Healthcare private in a $437m all-cash deal
Healthcare staffing is still under pressure. Knox Lane’s $437m Cross Country Healthcare deal turns that reset into a private equity wager.
Pharma & Biotech
Travere Therapeutics’ $475 million raise puts spotlight on rare disease execution risk
Rare disease pipelines need time and cash. Travere’s $475 million debt deal shows how biotech balance sheets are being rebuilt.
Pharma & Biotech
Can Contineum Therapeutics’ PIPE-791 become more than an IPF drug after fresh pain data?
Contineum Therapeutics advances PIPE-791 in IPF and chronic pain while extending cash runway into 2029. Find out what comes next.
Pharma & Biotech
How InflaRx N.V. plans to challenge avacopan in ANCA-associated vasculitis with izicopan
InflaRx N.V. is expanding izicopan into renal inflammation and vasculitis markets. Discover what this means for complement inhibitor competition.